244 related articles for article (PubMed ID: 19680616)
1. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
[TBL] [Abstract][Full Text] [Related]
2. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
3. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
4. WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma.
Koschny R; Krupp W; Xu LX; Mueller WC; Bauer M; Sinn P; Keller M; Koschny T; Walczak H; Bruckner T; Ganten TM; Holland H
Pathol Res Pract; 2015 Feb; 211(2):109-16. PubMed ID: 25481563
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
McCarthy MM; Sznol M; DiVito KA; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jul; 11(14):5188-94. PubMed ID: 16033835
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumour necrosis factor-alpha-related apoptosis-inducing ligand and its receptors in the adult human testis.
Grataroli R; Vindrieux D; Selva J; Felsenheld C; Ruffion A; Decaussin M; Benahmed M
Mol Hum Reprod; 2004 Feb; 10(2):123-8. PubMed ID: 14742697
[TBL] [Abstract][Full Text] [Related]
7. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Screaton G; Hersey P
Hum Pathol; 2006 Oct; 37(10):1286-94. PubMed ID: 16949935
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients.
Heilmann T; Vondung F; Borzikowsky C; Szymczak S; Krüger S; Alkatout I; Wenners A; Bauer M; Klapper W; Röcken C; Maass N; von Karstedt S; Schem C; Trauzold A
J Mol Med (Berl); 2019 Aug; 97(8):1155-1167. PubMed ID: 31183506
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations.
Tsikalakis S; Chatziandreou I; Michalopoulos NV; Theodoropoulos GE; Sakellariou S; Korkolopoulou P; Patsouris E; Saetta AA
Pathol Res Pract; 2018 Jun; 214(6):826-834. PubMed ID: 29731264
[TBL] [Abstract][Full Text] [Related]
11. Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.
Gallmeier E; Bader DC; Kriegl L; Berezowska S; Seeliger H; Göke B; Kirchner T; Bruns C; De Toni EN
PLoS One; 2013; 8(2):e56760. PubMed ID: 23460812
[TBL] [Abstract][Full Text] [Related]
12. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma.
Koschny R; Brost S; Hinz U; Sykora J; Batke EM; Singer S; Breuhahn K; Stremmel W; Walczak H; Schemmer P; Schirmacher P; Ganten TM
BMC Cancer; 2013 Nov; 13():532. PubMed ID: 24209510
[TBL] [Abstract][Full Text] [Related]
13. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
14. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
[TBL] [Abstract][Full Text] [Related]
15. The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.
Ullenhag GJ; Al-Attar A; Mukherjee A; Green AR; Ellis IO; Durrant LG
J Cancer Res Clin Oncol; 2015 Mar; 141(3):505-14. PubMed ID: 25230899
[TBL] [Abstract][Full Text] [Related]
16. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Tagscherer KE; Wagener N; Haferkamp A; Penzel R; Brauckhoff A; Hohenfellner M; Sykora J; Walczak H; Teh BT; Autschbach F; Herpel E; Schirmacher P; Roth W
Clin Cancer Res; 2009 Jan; 15(2):650-9. PubMed ID: 19147771
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.
Labovsky V; Martinez LM; Calcagno ML; Davies KM; García-Rivello H; Wernicke A; Feldman L; Giorello MB; Matas A; Borzone FR; Howard SC; Chasseing NA
Tumour Biol; 2016 Oct; 37(10):13377-13384. PubMed ID: 27460086
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
[TBL] [Abstract][Full Text] [Related]
20. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
